AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
02 sept. 2021 11h59 HE
|
AB Science
PRESS RELEASE AB SCIENCE TO PRESENT LATEST CLINICAL DATA ON LONG-TERM SURVIVAL ANALYSES IN AMYOTROPHIC LATERAL SCLEROSIS AT THE 2021 INTERNATIONAL SYMPOSIUM ON ALS/MND Paris, 2 September, 2021, 6pm...
ORPH BREAKING ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ORPH
24 août 2021 17h45 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
AB Science annonce avoir reçu la première autorisation de de reprise des inclusions dans l’étude de phase 3 confirmatoire du masitinib (AB19001) dans la SLA
23 août 2021 13h43 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR RECU LA PREMIERE AUTORISATION DE REPRISE DES INCLUSIONS DANS l’ETUDE DE PHASE 3 DU MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE (SLA) Paris,...
AB Science announces that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in ALS
23 août 2021 13h43 HE
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS RECEIVED THE FIRST AUTHORIZATION TO RESUME PATIENT ENROLLLMENT IN THE PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) Paris, 23...
AB Science annonce la publication d'un mécanisme pathogène déclenché par les mastocytes dans la moelle épinière de la sclérose latérale amyotrophique (SLA) qui peut être ciblé par le masitinib
19 août 2021 11h51 HE
|
AB Science
COMMUNIQUE DE PRESSE DE NOUVELLES DONNÉES RÉVÈLENT LE RÔLE DÉLÉTÈRE DES MASTOCYTES ACTIVÉS SUR LES MOTONEURONES DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE (SLA) ET L'EFFET PROTECTEUR OBSERVÉ LORS DU...
AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib
19 août 2021 11h51 HE
|
AB Science
PRESS RELEASE NEW DATA REVEAL THE DELETERIOUS ROLE OF ACTIVATED MAST CELLS ON MOTOR NEURONS IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND THE PROTECTIVE EFFECT OBSERVED UPON TREATMENT WITH MASITINIB ...
Amyotrophic Lateral Sclerosis Treatment Market Report to 2031: Visiongain Research Inc.
21 juil. 2021 14h00 HE
|
Visiongain Ltd
Visiongain has published a new report on Amyotrophic Lateral Sclerosis Treatment Market Report to 2031: Forecasts by Treatment Type (Chemotherapy and Stem Cell Therapy), By Distribution Channel...
AB Science annonce la publication de nouvelles données de survie montrant que le masitinib prolongeait la survie dans la SLA de 25 mois par rapport au placebo
19 juil. 2021 12h12 HE
|
AB Science
COMMUNIQUE DE PRESSE DE NOUVELLES DONNEES À LONG TERME SUR UNE DUREE DE 75 MOIS ONT MONTRÉ QUE LE MASITINIB PROLONGEAIT LA SURVIE DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE DE 25 MOIS PAR RAPPORT AU...
AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo
19 juil. 2021 12h12 HE
|
AB Science
PRESS RELEASE LONG-TERM FOLLOW-UP OF 75 MONTHS SHOWED THAT MASITINIB EXTENDED SURVIVAL IN AMYOTROPHIC LATERAL SCLEROSIS BY 25 MONTHS RELATIVE TO PLACEBO, PROVIDED THAT TREATMENT STARTS EARLY...
Amyotrophic Lateral Sclerosis Pipeline: Current Treatments, Drug Pipeline and Clinical Trial Outlook | Insights by DelveInsight
15 juin 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, June 15, 2021 (GLOBE NEWSWIRE) -- Amyotrophic Lateral Sclerosis Pipeline: Current Treatments, Drug Pipeline and Clinical Trial Outlook | Insights by DelveInsight The pipeline of...